Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600–Mutant Stage III Melanoma

Axel Hauschild, Georgina V. Long, Jacob Schachter et al.|Journal of Clinical Oncology|2018

Cited by 255